1600025M17Rik Inhibitors
Chemical inhibitors of the protein 1600025M17Rik can impede its function through various mechanisms depending on the particular kinase pathway it is involved in. Staurosporine, a potent protein kinase inhibitor, can inhibit a broad spectrum of kinases, therefore it can hinder the phosphorylation of 1600025M17Rik if it serves as a substrate for any of these kinases. Similarly, PP2, as a selective inhibitor of Src family tyrosine kinases, can impede the activity of these particular kinases, which in turn would inhibit the phosphorylation of 1600025M17Rik if this protein is indeed a substrate for Src kinases. On another front, LY294002 and Wortmannin, both inhibitors of PI3K, are capable of preventing the phosphorylation of proteins downstream of PI3K, consequently leading to an interruption in the activation of 1600025M17Rik if it lies within this pathway.
Inhibitors targeting the MEK/ERK pathway, such as PD0325901 and U0126, can also obstruct the functional activity of 1600025M17Rik by inhibiting the activation of the MAPK/ERK pathway. If 1600025M17Rik operates downstream of MEK, these inhibitors would therefore prevent its activation. Gefitinib and Erlotinib, both EGFR tyrosine kinase inhibitors, can inhibit downstream signaling pathways of EGFR, which would block the activation of 1600025M17Rik if it is associated with EGFR signaling. The mTOR inhibitor Rapamycin has the capacity to block the function of proteins involved in cell growth and proliferation, which may include 1600025M17Rik. In addition, SP600125, an inhibitor of JNK, can impede the phosphorylation of substrates within the JNK pathway, which would prevent the functional activity of 1600025M17Rik if it is a JNK substrate. SB203580, which selectively inhibits p38 MAP kinase, can similarly block the activation of 1600025M17Rik if it is a substrate of p38 MAPK. Lastly, Dasatinib, with its broad-spectrum inhibition of tyrosine kinases, can prevent the tyrosine phosphorylation of numerous proteins, thereby inhibiting the activity of 1600025M17Rik if it is among those proteins phosphorylated by these kinases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases, which may include kinases that phosphorylate 1600025M17Rik, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. It can inhibit the activity of these kinases, hence potentially inhibiting the phosphorylation and subsequent activity of 1600025M17Rik, if it is a substrate for Src kinases. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which is involved in the Akt signaling pathway. Inhibition of PI3K could inhibit the phosphorylation of downstream proteins, which may include 1600025M17Rik, thus leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can prevent the activation of the PI3K/Akt pathway, potentially leading to functional inhibition of 1600025M17Rik by blocking its phosphorylation if it is downstream of PI3K. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which could lead to the inhibition of its downstream signaling pathways. If 1600025M17Rik is activated by EGFR signaling, its functional activity would be inhibited. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, similar to gefitinib, inhibits EGFR and could functionally inhibit 1600025M17Rik by blocking downstream signaling pathways that might contribute to the activity of this protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. Inhibition of mTOR can lead to functional inhibition of downstream proteins involved in these processes, possibly including 1600025M17Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and by inhibiting JNK, it could hinder the phosphorylation of substrates that are part of the JNK signaling pathway, which may functionally inhibit 1600025M17Rik if it is a JNK substrate. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. Inhibition of p38 MAPK could lead to the functional inhibition of 1600025M17Rik if it is a p38 MAPK substrate, thereby blocking its activation and function within the signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that can prevent tyrosine phosphorylation of many proteins. If 1600025M17Rik is a tyrosine kinase substrate, dasatinib could functionally inhibit its activity by blocking its phosphorylation. | ||||||